Literature DB >> 15232662

A comparison of the pharmacokinetics of tacrolimus and microemulsified cyclosporin in paediatric renal transplant recipients.

Kenneth W Renton1, John F S Crocker, Heather McLellan, Philip D Acott.   

Abstract

OBJECTIVE: Our objective was to identify common factors that determine the dose of tacrolimus and microemulsified cyclosporin in paediatric renal transplant recipients.
METHODS: The concentration profiles of tacrolimus and cyclosporin in blood were determined in 68 children who had received a renal transplant. To avoid disruption of therapy, measurements were made at 2-h intervals over an 8-h period during normal dosing regimens. Direct comparisons of the two drugs were made in 14 of the subjects who were switched from cyclosporin to tacrolimus.
RESULTS: The ratio of peak to trough levels for tacrolimus was approximately twofold compared with over threefold for cyclosporin. Area under the curve (AUC) for tacrolimus remained relatively constant in each 2-h period of the dosage interval compared with the AUC for cyclosporin, which varied by over twofold in the same time period. In the 14 subjects who received both drugs, there was a poor correlation between C2/C0, C2, t(1/2) and AUC for tacrolimus and cyclosporin in the same individual. In a multivariate analysis, there were no significant associations for tacrolimus concentrations, AUC or C2/C0 with age, gender, calcium-channel blocker, quinolone or statin. For cyclosporin, there was some association for AUC with gender and quinolone use and a weak association with calcium-channel blocker or statin use.
CONCLUSIONS: Tacrolimus and microemulsified cyclosporin display a wide intra- and inter-individual variation in pharmacokinetic properties in young subjects. In the case of absorption represented by the peak-trough ratios, the values for tacrolimus are significantly less than those obtained with cyclosporin. The pharmacokinetic parameters obtained for one of these agents is not predictive for the behaviour of the other in young renal transplant recipients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15232662     DOI: 10.1007/s00228-004-0773-9

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  43 in total

1.  One-year glomerular filtration rate predicts graft survival in pediatric renal recipients: a randomized trial of tacrolimus vs cyclosporine microemulsion.

Authors:  G Filler; R Trompeter; N J A Webb; A R Watson; D V Milford; G Tyden; R Grenda; J Janda; D Hughes; G Offner; B Klare; G Zacchello; I B Brekke; M McGraw; F Perner; L Ghio; E Balzar; S Friman; R Gusmano; J Stolpe
Journal:  Transplant Proc       Date:  2002-08       Impact factor: 1.066

Review 2.  Pharmacokinetics and therapeutic drug monitoring of immunosuppressants.

Authors:  A Lindholm; J Säwe
Journal:  Ther Drug Monit       Date:  1995-12       Impact factor: 3.681

3.  Tacrolimus clearance is age-dependent within the pediatric population.

Authors:  D Przepiorka; D Blamble; S Hilsenbeck; M Danielson; R Krance; K W Chan
Journal:  Bone Marrow Transplant       Date:  2000-09       Impact factor: 5.483

4.  Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation.

Authors:  Richard Trompeter; Guido Filler; Nicholas J A Webb; Alan R Watson; David V Milford; Gunnar Tyden; Ryszard Grenda; Jan Janda; David Hughes; Jochen H H Ehrich; Bernd Klare; Graziella Zacchello; Inge Bjorn Brekke; Mary McGraw; Ferenc Perner; Lucian Ghio; Egon Balzar; Styrbjörn Friman; Rosanna Gusmano; Jochen Stolpe
Journal:  Pediatr Nephrol       Date:  2002-03       Impact factor: 3.714

5.  Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily.

Authors:  J Combalbert; I Fabre; G Fabre; I Dalet; J Derancourt; J P Cano; P Maurel
Journal:  Drug Metab Dispos       Date:  1989 Mar-Apr       Impact factor: 3.922

6.  Long-term cyclosporin A pharmacokinetic profiles in pediatric renal transplant recipients.

Authors:  A Kelles; R Van Damme-Lombaerts; T B Tjandra-Maga; B Van Damme
Journal:  Transpl Int       Date:  1996       Impact factor: 3.782

7.  Optimal use of tacrolimus in living donor renal transplantation in children.

Authors:  A Hasegawa; K Takahashi; K Ito; S Oshima; K Uchida; T Sonoda
Journal:  Transplant Proc       Date:  2002-08       Impact factor: 1.066

Review 8.  Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.

Authors:  D H Peters; A Fitton; G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

9.  The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients.

Authors:  Charles R Yates; Wenhui Zhang; Pengfei Song; Shen Li; A Osama Gaber; Malak Kotb; Marsha R Honaker; Rita R Alloway; Bernd Meibohm
Journal:  J Clin Pharmacol       Date:  2003-06       Impact factor: 3.126

10.  Therapeutic drug monitoring of tacrolimus: a moving matter.

Authors:  C Manzanares
Journal:  Therapie       Date:  2002 Mar-Apr       Impact factor: 2.070

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.